DSM-Firmenich stock edges lower as share buyback nears completion and analyst rating is cut

Published on 09/08/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock trades slightly below recent levels on Euronext Amsterdam as the company reports further progress on its EUR 540 million share buyback program and Rothschild Co Redburn downgrades the stock to neutral with a marginally lower price target.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich stock (ISIN CH1216478797) was quoted at 92.82 euros on Euronext Amsterdam in real-time trading on September 8, 2026, down 0.71 percent from the previous close of 93.48 euros, while the year-to-date performance remains up 34.99 percent according to Zonebourse.

Share buyback program approaches key milestone

On September 8, 2026, DSM-Firmenich reported fresh progress on its ongoing share repurchase program, confirming that between August 31, 2026 and September 4, 2026 it bought back 275,000 shares at an average price of 94.52 euros per share for a total consideration of 26.0 million euros, as detailed in a press release distributed via Yahoo Finance.

The company stated that, since the start of the program on March 12, 2026, it has repurchased a cumulative 6,017,212 shares at an average price of 71.69 euros, for a total value of 431.4 million euros, indicating that over 79 percent of the announced 540 million euro program has already been executed by early September 2026 according to the same release from Yahoo Finance.

Capital reduction and employee share plans in focus

DSM-Firmenich originally announced on February 9, 2026 that it would repurchase ordinary shares with an aggregate market value of 500 million euros to reduce its issued capital, supplemented by 40 million euros to cover commitments under its share-based compensation plans, a framework that was reiterated in the September 8, 2026 update via Yahoo Finance.

The company confirmed that the 40 million euro portion of the buyback dedicated to employee share plans was fully completed by March 23, 2026, while the remaining 500 million euro tranche for capital reduction is intended to be finalized by the end of the third quarter of 2026, signaling a clear timetable for balance sheet optimization and shareholder returns as laid out in the same release from Yahoo Finance.

Analyst downgrade trims price target

On September 8, 2026, research house Rothschild Co Redburn cut its recommendation on DSM-Firmenich from buy to hold and reduced its price target from 94 euros to 93 euros, a modest 1.06 percent reduction, according to Zonebourse analyst coverage.

The consensus data from Zonebourse show that the average target price for DSM-Firmenich currently stands at 93.62 euros, only 0.15 percent above the last closing price of 93.48 euros, suggesting that the market sees limited upside near the current trading range despite the strong 34.99 percent gain since the start of 2026.

Next trading update scheduled

In addition to the capital measures and analyst moves, DSM-Firmenich has scheduled its next trading update on activity for the third quarter of 2026 for November 4, 2026, as indicated in the agenda section of Zonebourse.

For investors, this upcoming Q3 2026 activity publication will offer a more detailed view of how the share buyback program, recent governance changes and industry dynamics in nutrition, health and beauty are feeding through to revenue trends and margins, complementing the capital structure information already disclosed.

Nutrition, health and beauty portfolio

DSM-Firmenich positions itself as a leading innovator in nutrition, health and beauty, combining vital nutrients, flavors and fragrances with natural and renewable ingredients, as described in the September 8, 2026 company profile included in the press release distributed via Yahoo Finance.

Stock price and market context

As of the real-time snapshot at 16:32:31 on September 8, 2026, DSM-Firmenich stock traded at 92.82 euros on Euronext Amsterdam, 0.71 percent below the prior close of 93.48 euros, while the year-to-date performance of plus 34.99 percent highlights a robust recovery over 2026 according to Zonebourse.